Research
Orbital and preseptal cellulitis are on the rise in the US
Study finds the incidence rate of preseptal cellulitis has increased three-fold since 2006.
Pipeline
Opus Genetics reports first-in-human trial data on LCA gene therapy
One-month findings from the first of three pediatric dosings indicate a clinically meaningful improvement in vision following just one dosing.
Research
Do personality traits play a role in DED development?
New study links higher neuroticism, lower conscientiousness to increased odds of dry eye disease.
Products
FDA grants ANDA approval to olopatadine hydrochloride for ocular allergy relief
Generic of Alcon’s Pataday Once Daily Relief is intended for use as an antihistamine to treat itchy eyes.
Business
Opthea to cut workforce by an estimated 65%
Significant layoffs follow in wake of the company's phase 3 trial failures and subsequent termination of its wet AMD program late last month.
Business
How will reciprocal tariffs impact the optical industry?
The Vision Council updates industry members as the U.S. imposes new 10% tariffs on 60+ countries across the globe—and 125% on China.
Pipeline
FDA accepts Outlook Therapeutics' bevacizumab BLA for wet AMD
With a PDUFA date of Aug. 27, ONS-5010 (LYTENAVA) could become the first FDA-approved bevacizumab formulation targeting this retinal disease.
Research
Daily hour of screen time increases myopia risk by nearly 25%
Investigators report significant increase in myopia risk seen with up to 4 hours of daily screen time, after which the risk rose more gradually.
Pipeline
Tenpoint submits NDA for Brimochol PF for presbyopia
The FDA begins a 60-day review period to determine if the submission for the pupil-modulating eye drop is acceptable.
Pipeline
Avisi reports positive 6-month data on VisiPlate aqueous shunt for glaucoma
MIBS device composed of non-fibrotic nanotechnology-based metamaterials lowered OAG patients’ mean IOP by 40%.
Research
Hormones may play key role in DR risk among diabetes patients
Surprising findings reveal how sex hormones may secretly influence the risk for diabetic retinopathy.
Products
Orasis's QLOSI for presbyopia launches in the US
Pilocarpine 0.4% provides patients with flexible dosing for up to 8 hours of clear near vision; prescription-based drops are available through two pharmacy partners.
Legal
New North Dakota bill establishes optometric telemedicine guidelines
Legislation prioritizes patient safety and increased access to standardized virtual care across the state.
Products
Avulux migraine glasses added to federal pediatric medical device accelerator
FDA-funded MedTech organization will provide resources to support unique precision lens tech, designed to block up to 87% of harmful and mitigate photophobia effects.
Research
Lifestyle habits may benefit cognitive impairment in glaucoma
Mindfulness meditation may help slow the rate of neurocognitive decline.
Products
Hoya introduces VisuPro All Day and Flex lenses for young presbyopes
Advanced spectacle lenses target adult patients experiencing an initial gradual loss of vision.
Pipeline
FDA rejects Aldeyra's reproxalap NDA for a second time
Agency states the candidate failed to demonstrate efficacy in treating ocular symptoms associated with dry eyes; company plans for a third submission.
Products
Alcon launches Clareon PanOptix Pro IOL in the US
With a broad commercial rollout planned for next month, this will be the company’s first presbyopia-correcting IOL available in its Clareon AutonoMe preloaded system.
Pipeline
OKYO's urcosimod demonstrates long-term stability for NCP
With a real-world study ongoing, urcosimod’s +2.5-year shelf stability further supports a potential NDA submission for regulatory approval down the road.
Research